Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen.
The release of 6-keto-prostaglandin F1 alpha(6-keto-PGF1 alpha), a metabolite of prostacyclin (PGI2) and thromboxane B2 (TxB2), a metabolite of thromboxane A2 (TxA2), was estimated in endometrial biopsies taken from 12 menorrhagic and 12 healthy women during the luteal phase of the cycle. The releases of 6-keto-PGF1 alpha and TxB2 were normal, but the ratio TxB2/6-keto-PGF1 alpha was inversely related to menstrual blood loss in women with measured menstrual blood loss exceeding 70 ml. In the second part of the study, 24 women with excessive menstrual bleeding (13 with primary menorrhagia, 10 with uterine fibromyomas, one with haemostatic factor VIII deficiency) were treated at random with ibuprofen (600 mg/day and 1200 mg/day) and with a placebo. Ibuprofen 1200 mg/day reduced (P less than 0.01) median blood loss from 146 ml (range 71-374 ml) to 110 ml (30-288 ml) in primary menorrhagia but had no effect on blood loss in women with uterine fibroids and factor VIII deficiency. Blood loss was normal in six women and was not affected by ibuprofen. Thus, our data suggest that there is a PGI2 dominance in the endometrium of patients with menorrhagia. In addition, primary, but neither fibromyoma nor coagulation defect-associated menorrhagia, can be treated by ibuprofen.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004717:Endometrium / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D007889:Leiomyoma / Q000150:complications*; D008595:Menorrhagia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D008875:Middle Aged; D011897:Random Allocation; D013928:Thromboxane A2 / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000150:complications*
D013928:Thromboxane A2; D011464:Epoprostenol; D007052:Ibuprofen